• LeukoPrint®

    The first-in-class leukemia sWGS CNA test

    By evaluating the copy number aberration (CNA) in bone marrow cells and/or circulating cell free DNA (cfDNA) via shallow whole genome sequencing (sWGS), in conjunction with conventional cytogenetics, LeukoPrint® makes leukemia diagnosis, molecular subtyping, prognostic stratification and treatment responds monitoring more precise and comprehensive.

  • High sensitivity and low failure rate

    Automatic readout system

    Without culturing cells in vitro

  • Specifications

    Sample requirement:1-2ml bone marrow or 10ml blood

    TAT:10 work days
    Result readout:copy number aberration(CNA)

    Indicated subjects:Patients with suspected or confirmed leukemia (MDS/AML/ALL/CLL/MM)

  • Test Workflow

    1

    Pre-test inquiry

    2

    Informed consent

    3

    Sampling

    4

    Testing

    5

    Analyzing + Interpretation

    6

    Reporting

    7

    Post-test consultation

    所有文章
    ×

    ©2018 SeekIn Cancer. All Rights Reserved.